OBJECTIVE: The aim of the present review has been to provide an overview of the current status of castration-resistant prostate cancer and to share the high expectations created with the new treatments.
EVIDENCE ACQUISITION: Evidence was obtained from multidisciplinary meetings with the participation of urologists and oncologists, where they pooled the analysis of original articles in the literature and defined the content of the article.
EVIDENCE SYNTHESIS: Chemotherapy with docetaxel was a turning point in castration-resistant prostate cancer after the failure of hormonal therapy failure. For the first time, it achieved increased survival time in comparison with mitoxantrone and prednisone. Combination therapy with docetaxel and prednisone is the first-line choice treatment. Once the cancer has progressed, there is no clear alternative, although some novel agents have created expectations for the treatment of this type of cancer.
CONCLUSIONS: The range of therapeutic options for castration-resistant prostate cancer has increased dramatically with the arrival of new drugs. At present, cabazitaxel, and in the near future, abiraterone, have been found to be effective drugs in second-line treatment after progression to docetaxel, increasing survival by 2-4 months and reducing risk of death by 30-35%.
Written by:
Alcaraz A, Medina R, Maroto P, Climent MA, Castellano D, Carles J. Are you the author?
Servicio de Urología, IDIBAPS, Hospital Clínic de Barcelona, Barcelona, España.
Reference: Actas Urol Esp. 2011 Dec 19. Epub ahead of print.
doi: 10.1016/j.acuro.2011.10.01
PubMed Abstract
PMID: 22188754
Article in English, Spanish.
UroToday.com Prostate Cancer Section
